Keywords: novartis, looks, ibs, drug, zelnorm, its, next
Novartis looks to IBS drug Zelnorm as its next blockbuster earner
Article | 04 October 2004
Novartis is optimistic that its irritable bowel syndrome treatment Zelnorm/Zelmac (tegaserod) has blockbuster potential, a senior company spokesman revealed ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
